Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Lyon Cedex 9, France Clinical Trials

A listing of Lyon Cedex 9, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (31) clinical trials

Study of the Impact of a Targeted Decolonization of S. Aureus Persistent Carriers

Hemodialysis patients will be randomized in 2 arms: one arm where persistent carriers will be decolonized. Decolonization schedule associate the use of mupirocin nasal ointment 3 times a day and chlorhexidine bath once a day for 5 days. Screening of persistent carriers in this arm will be done every 3 ...

Phase

0.0 miles

Learn More »

A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease

The FAME 3 trial is a multicenter, international, randomized, controlled noninferiority trial. All patients with multivessel CAD (not involving the left main) will be screened by the site's Heart Team (including but not limited to an interventional cardiologist, cardiac surgeon and research coordinator). If all agree that the patient can ...

Phase

0.0 miles

Learn More »

Evaluation of Therapeutic Strategies for Treatment of Ectopic Pregnancies (EP) and Evaluation of Subsequent Fertility

The first group includes non active ectopic pregnancies defined by score or algorithm. In this case, we propose a randomized controlled trial between medical and conservative surgery. In all others clinical situations, we proposed surgery treatment. In a randomized controlled trial we compare conservative versus radical treatment. The patients are ...

Phase

0.0 miles

Learn More »

A Study of Two Different Doses of Cabozantinib (XL184) in Progressive Metastatic Medullary Thyroid Cancer

The objective of this study is to evaluate the efficacy and safety of oral cabozantinib at a 60 mg dose compared with a 140 mg dose in subjects with progressive, metastatic MTC. It will test if the lower dose results in similar progression free survival (PFS) and overall response rate ...

Phase

0.0 miles

Learn More »

Tranexamic Acid to Reduce Blood Loss in Hemorrhagic Caesarean Delivery

Postpartum hemorrhage (PPH) is the leading cause of maternal death. Tranexamic acid (TA) (Exacyl Sanofi France), an antifibrinolytic drug, reduces bleeding and transfusion need in major surgery and trauma (1). In ongoing PPH following vaginal delivery (2), a high dose of TA decreased the volume and duration of PPH, the ...

Phase

0.0 miles

Learn More »

STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction

In elderly patients 60yrs with acute ST-elevation myocardial infarction randomised within 3 hours of onset of symptoms the efficacy and safety of a strategy of early fibrinolytic treatment with half-dose tenecteplase and additional antiplatelet therapy with a loading dose of 300 mg clopidogrel, aspirin and coupled with antithrombin therapy followed ...

Phase

0.0 miles

Learn More »

Comparison of Angioplasty/Drug Coated Balloon/Laser + Drug Coated Balloon for Femoropopliteal Artery In-stent Restenosis

The publication show that there is probably an effectiveness gradient (expressed as a proportion of patients with in-stent restenosis a 18 months after the intervention of the first stenosis reduction): standard balloons would be less effective than active balloons themselves less effective than in combination with the excimer laser. Reducing ...

Phase

0.0 miles

Learn More »

A Study of the Impact of Apremilast (CC-10004) on Quality of Life Efficacy and Safety in Subjects With Manifestations of Plaque Psoriasis and Impaired Quality of Life

This is a Phase 4, multi-center, randomized, placebo-controlled, double-blind study of the impact of apremilast on quality of life, efficacy, and safety in subjects with manifestations of plaque psoriasis and impaired quality of life. Approximately 255 subjects will be randomized 2 (apremilast):1 (placebo) in approximately 6 to 10 countries in ...

Phase

0.0 miles

Learn More »

Trial of Andexanet in ICH Patients Receiving an Oral FXa Inhibitor

This is a randomized, multicenter clinical trial designed to determine the efficacy and safety of andexanet compared to usual care in patients presenting with acute intracranial hemorrhage within 12 hours of symptom onset and within 15 hours of taking an oral factor Xa inhibitor. The study will use a prospective, ...

Phase

0.0 miles

Learn More »

NIraparib and Quality Of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib.

The aim of NiQoLe is to evaluate tolerability of Niraparib and the management by the physicians of the side-effects in real life in France. The study will also generate data on longitudinal follow up of closed symptoms and side effects reported by the patients especially with the NCI PRO (Patient-Reported ...

Phase

0.0 miles

Learn More »